Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Two year clinical experience after combined cataract surgery and supraciliary micro-stent implantation for the treatment of glaucoma

Poster Details

First Author: H.Höh GERMANY

Co Author(s):    S. Grisanti   A. Anton   S. Grisanti   I. Ahmed   T. Ianchulev  

Abstract Details



Purpose:

Evaluate the safety and efficacy of supraciliary micro-stent implantation in conjunction with cataract surgery, as well as changes in intraocular pressure (IOP) and use of glaucoma medications (meds).

Setting:

Multi-site clinical study in Europe and Canada

Methods:

Ongoing multicenter interventional case series (CyCLE study). Investigators performed standard small-incision cataract surgery followed by implantation of the suprachoroidal CyPass Micro-Stent (Transcend Medical, Inc, Menlo Park, CA) into the supraciliary space through the phaco incision. All 136 eyes of 136 patients had reached the 24 month (M) time point after surgery.

Results:

The safety was consistent with a MIGS procedure. No major adverse events, such as choroidal hemorrhage, hypotony maculopathy, or endophthalmitis, occurred in the 24M follow-up period. In patients with uncontrolled IOP (? 21 mmHg) at baseline (n=51), mean IOP decreased from 25.5 + 4.9 mmHg at baseline to 15.8 + 3.8 mmHg at 24M with a concomitant 52% reduction in medication use. In patients with controlled IOP at baseline (n=85), IOP was maintained from 16.4 + 2.7 mmHg at baseline to 16.1 + 3.2 mmHg at 24M with a concomitant 48% reduction in medication use.

Conclusions:

CyPass Micro-Stent implantation is a minimally invasive intervention for the treatment of open-angle glaucoma that spares the conjunctiva, sclera and trabecular meshwork, can be performed in conjunction with small-incision cataract surgery, and shows sustained control of IOP and decreased need for glaucoma meds in eyes 2 year postoperative.

Financial Disclosure:

... is employed by a for-profit company with an interest in the subject of the presentation, ... research is funded, fully or partially, by a competing company, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... receives consulting fees, retainer, or contract payments from a competing company, ... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented

Back to previous